[go: up one dir, main page]

MA44209B1 - Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate - Google Patents

Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate

Info

Publication number
MA44209B1
MA44209B1 MA44209A MA44209A MA44209B1 MA 44209 B1 MA44209 B1 MA 44209B1 MA 44209 A MA44209 A MA 44209A MA 44209 A MA44209 A MA 44209A MA 44209 B1 MA44209 B1 MA 44209B1
Authority
MA
Morocco
Prior art keywords
phosphorodiamidate oligomer
phosphorodiamidate
oligomer
preparation
pharmaceutical composition
Prior art date
Application number
MA44209A
Other languages
English (en)
Other versions
MA44209A (fr
Inventor
Atsushi Endo
Robert T Yu
Francis Fang
Hyeong Wook Choi
Mingde Shan
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA44209A publication Critical patent/MA44209A/fr
Publication of MA44209B1 publication Critical patent/MA44209B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des nucléosides morpholino phosphoramidochloridate activés diastéréomériquement purs ou sensiblement diastéréomériquement purs, des procédés pour leur préparation, et des procédés pour leur utilisation en couplage stéréospécifique pour la synthèse stéréospécifique d'oligomères morpholino phosphorodiamidate (pmo) diastéréomériquement purs.
MA44209A 2015-08-05 2016-08-05 Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate MA44209B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201510P 2015-08-05 2015-08-05
PCT/US2016/045876 WO2017024264A2 (fr) 2015-08-05 2016-08-05 Réactifs chiraux pour la préparation d'oligomères homogènes

Publications (2)

Publication Number Publication Date
MA44209A MA44209A (fr) 2021-04-28
MA44209B1 true MA44209B1 (fr) 2022-03-31

Family

ID=56943909

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44209A MA44209B1 (fr) 2015-08-05 2016-08-05 Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate

Country Status (31)

Country Link
US (4) US10457698B2 (fr)
EP (2) EP3331891B1 (fr)
JP (4) JP6978406B2 (fr)
KR (2) KR20250005537A (fr)
CN (3) CN108350005B (fr)
AU (3) AU2016302009B2 (fr)
CA (1) CA2994842A1 (fr)
CL (1) CL2018000322A1 (fr)
CO (1) CO2018001615A2 (fr)
CY (1) CY1125552T1 (fr)
DK (1) DK3331891T3 (fr)
ES (2) ES2907629T3 (fr)
HR (1) HRP20220129T1 (fr)
HU (2) HUE057593T2 (fr)
IL (3) IL293066A (fr)
LT (1) LT3331891T (fr)
MA (1) MA44209B1 (fr)
MD (1) MD3331891T2 (fr)
MX (2) MX389022B (fr)
MY (1) MY196627A (fr)
NZ (2) NZ778825A (fr)
PE (2) PE20231843A1 (fr)
PH (1) PH12018500265A1 (fr)
PL (1) PL3331891T3 (fr)
PT (1) PT3331891T (fr)
RS (1) RS62930B1 (fr)
SI (1) SI3331891T1 (fr)
SM (1) SMT202200089T1 (fr)
UA (1) UA123995C2 (fr)
WO (1) WO2017024264A2 (fr)
ZA (3) ZA201801518B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293066A (en) * 2015-08-05 2022-07-01 Eisai R&D Man Co Ltd Chiral reagents for the preparation of homogeneous oligomers
WO2018057430A1 (fr) * 2016-09-20 2018-03-29 The Regents Of The University Of Colorado, A Body Corporate Synthèse d'oligonucléotides morpholino modifiés par squelette et chimères utilisant la chimie phosphoramidite
MY209476A (en) 2019-12-26 2025-07-11 Nippon Shinyaku Co Ltd Antisense nucleic acid that induces skipping of exon 50
KR20220145865A (ko) 2020-02-28 2022-10-31 니뽄 신야쿠 가부시키가이샤 엑손 51의 스키핑을 유도하는 안티센스 핵산
US20220195437A1 (en) 2020-12-11 2022-06-23 Eisai R&D Management Co., Ltd. Tau-targeting oligonucleotide gapmers
CN117120456A (zh) 2020-12-11 2023-11-24 卫材R&D管理有限公司 聚-吗啉代寡核苷酸缺口体
IL307787A (en) 2021-04-28 2023-12-01 Eisai R&D Man Co Ltd ANTISENSE OLIGONUCLEOTIDES and their use for the treatment of neurodegenerative disorders
JP2025521879A (ja) * 2022-07-07 2025-07-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 アンチセンス・オリゴヌクレオチドを調製するための結晶性モノマー、並びにそれらの調製及び使用の方法
TW202432183A (zh) 2022-10-27 2024-08-16 日商衛材R&D企管股份有限公司 肽—反義寡核苷酸及其用於治療神經退行性障礙之用途
EP4658280A2 (fr) * 2023-02-01 2025-12-10 Alnylam Pharmaceuticals, Inc. Cycle à six chaînons contenant des oligomères

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US6117993A (en) 1995-05-23 2000-09-12 Hybridon, Inc. Synthons for oligonucleotide synthesis
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5874554A (en) 1996-12-13 1999-02-23 Incyte Pharmaceuticals, Inc. Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices
US6306599B1 (en) 1999-07-16 2001-10-23 Agilent Technologies Inc. Biopolymer arrays and their fabrication
EP1176151B1 (fr) * 2000-07-28 2014-08-20 Agilent Technologies, Inc. Synthèse des polynucléotides utilisant la chimie combinée d'oxidation et de protection
AR036122A1 (es) 2001-07-03 2004-08-11 Avecia Biotechnology Inc Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
HRP20140646T1 (hr) * 2007-11-15 2014-09-26 Sarepta Therapeutics, Inc. Postupak sinteze morfolino oligomera
US9914745B2 (en) 2009-08-14 2018-03-13 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
TWI620756B (zh) * 2010-05-28 2018-04-11 薩羅塔治療公司 具有經修飾之單元間連結及／或末端基團之寡核苷酸類似物
KR101764462B1 (ko) * 2010-09-30 2017-08-02 니뽄 신야쿠 가부시키가이샤 모르폴리노 핵산 유도체
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR102229650B1 (ko) * 2011-05-05 2021-03-19 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
CN113264959A (zh) 2011-10-07 2021-08-17 吉利德科学公司 制备抗病毒核苷酸类似物的方法
EA202090338A1 (ru) 2011-11-18 2021-04-30 Сарепта Терапьютикс, Инк. Функционально-модифицированные олигонуклеотиды и их субъединицы
EP2785729B1 (fr) 2011-11-30 2020-11-04 Sarepta Therapeutics, Inc. Oligonucléotides pour le traitement de maladies à répétition étendue
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
IL293066A (en) * 2015-08-05 2022-07-01 Eisai R&D Man Co Ltd Chiral reagents for the preparation of homogeneous oligomers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MX2018001522A (es) 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.
DE102015214943A1 (de) 2015-08-05 2017-02-09 Siemens Aktiengesellschaft Verfahren und Anlage für eine chemische Synthese

Also Published As

Publication number Publication date
JP7254869B2 (ja) 2023-04-10
MA44209A (fr) 2021-04-28
US10836784B2 (en) 2020-11-17
AU2023226763A1 (en) 2023-09-28
JP2022003067A (ja) 2022-01-11
RU2018107663A3 (fr) 2020-05-21
EP4039690C0 (fr) 2024-07-17
CN108350005B (zh) 2024-02-06
CL2018000322A1 (es) 2018-05-18
EP4039690B1 (fr) 2024-07-17
SMT202200089T1 (it) 2022-03-21
IL284611B1 (en) 2023-07-01
NZ778828A (en) 2024-11-29
AU2021290235B2 (en) 2023-06-08
AU2016302009B2 (en) 2021-09-30
ZA201801518B (en) 2020-10-28
LT3331891T (lt) 2022-02-25
MD3331891T2 (ro) 2022-04-30
CN117924364A (zh) 2024-04-26
RU2018107663A (ru) 2019-09-05
EP3331891A2 (fr) 2018-06-13
JP2023085402A (ja) 2023-06-20
AU2016302009A1 (en) 2018-03-29
WO2017024264A3 (fr) 2017-03-30
KR102788397B1 (ko) 2025-04-01
HUE057593T2 (hu) 2022-05-28
HUE067910T2 (hu) 2024-11-28
US20180222932A1 (en) 2018-08-09
JP7712975B2 (ja) 2025-07-24
SI3331891T1 (sl) 2022-04-29
CA2994842A1 (fr) 2017-02-09
ZA201905394B (en) 2022-07-27
US20250171475A1 (en) 2025-05-29
US20200115405A1 (en) 2020-04-16
NZ740490A (en) 2024-07-05
JP2018525380A (ja) 2018-09-06
EP4039690A1 (fr) 2022-08-10
EP3331891B1 (fr) 2021-12-15
IL257353B2 (en) 2023-02-01
AU2023226763B2 (en) 2025-09-18
MX389022B (es) 2025-03-20
ZA202201010B (en) 2024-05-30
PT3331891T (pt) 2022-02-28
IL284611B2 (en) 2023-11-01
MX2018001557A (es) 2018-05-02
HK1248708A1 (zh) 2018-10-19
IL257353B (en) 2022-10-01
CY1125552T1 (el) 2024-02-16
NZ778825A (en) 2024-11-29
BR122023025447A2 (pt) 2024-01-16
PE20231843A1 (es) 2023-11-21
MY196627A (en) 2023-04-23
HRP20220129T1 (hr) 2022-04-15
US20210171555A1 (en) 2021-06-10
KR20250005537A (ko) 2025-01-09
MX2022000124A (es) 2022-02-16
RS62930B1 (sr) 2022-03-31
UA123995C2 (uk) 2021-07-07
ES2993126T3 (en) 2024-12-23
CN113461733A (zh) 2021-10-01
PH12018500265A1 (en) 2018-08-13
IL257353A (en) 2018-04-30
BR112018002430A2 (pt) 2018-09-18
WO2017024264A2 (fr) 2017-02-09
ES2907629T3 (es) 2022-04-25
WO2017024264A8 (fr) 2018-04-12
IL284611A (en) 2021-08-31
CO2018001615A2 (es) 2018-07-19
PL3331891T3 (pl) 2022-03-28
US10457698B2 (en) 2019-10-29
PE20180687A1 (es) 2018-04-23
KR20180044303A (ko) 2018-05-02
JP2025090640A (ja) 2025-06-17
CN108350005A (zh) 2018-07-31
AU2021290235A1 (en) 2022-01-20
JP6978406B2 (ja) 2021-12-08
IL293066A (en) 2022-07-01
DK3331891T3 (da) 2022-02-28

Similar Documents

Publication Publication Date Title
MA44209B1 (fr) Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate
MX2024007103A (es) Metodos de purificacion por columna de vectores aav.
ZA201708667B (en) Tyrosine kinase inhibitors
EP4516301A3 (fr) Composés contenant du nitrile pour utilisation comme médicaments
MY209319A (en) Compounds useful to treat influenza virus infections
MA43335A (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MY205512A (en) Arginase inhibitors
MX392008B (es) Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
MY200590A (en) Compounds useful as kinase inhibitors
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MX386086B (es) Composicion de cannabis
MX2018002099A (es) Compuestos y métodos para la administración transmembranal de moléculas.
MX2018002665A (es) Combinacion que comprende oligonucleotidos inmunoestimulantes.
PH12017500944A1 (en) New 2` and/or 5` amino-acid ester phosphoramidate 3`-deoxy adenosine derivatives as anti-cancer compounds
JOP20200041A1 (ar) تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
MA45620A (fr) Oligonucléotides antisens pour la modulation de l'expression de htra1
NZ728073A (en) 6-alkynyl-pyridine derivatives as smac mimetics
MX2022003365A (es) Anticuerpos de un solo dominio dirigidos contra lilrb2.
ZA202204730B (en) Oligonucleotides with nucleoside analogs
MX2025006740A (es) Composiciones farmacéuticas que contienen una de piperidinil-metil-purina amina y su uso en el tratamiento de enfermedades y afecciones
BR112016028842A2 (pt) ?aparelho e processo para separar um produto alvo?
MX2021013602A (es) Inhibidores de jak.
MX2018012197A (es) Dispositivo para transportar y retener una hoja de vidrio, particularmente en una instalacion de lavado.
WO2016187620A3 (fr) Composés anti-cancereux